BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales

California-based drugmaker Gilead Sciences GILD.O posted Q4 results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday driven by 16% jump in HIV drug sales and lower acquisition-related costs

Shares of GILD up 4.54% at $100.50 in premarket trading on Wednesday

A HEALTHY PROGNOSIS

J.P.Morgan ("overweight," PT: $120) sees developments in HIV prevention and treatment, oncology, and a new drug launch for primary biliary cholangitis (PBC) in 2025, leading to optimism about co's future

Mizuho ("outperform," PT: $100) sees strong HIV sales growth but anticipates a significant headwind in 2025 due to Medicare changes

Piper Sandler ("overweight," PT: $110) sees strong growth in HIV and liver disease treatments, stable FY25 revenue despite headwinds, and anticipates operating margin expansion and key clinical milestones

RBC Capital Markets ("sector perform," PT: $90) says they are cautious about complexities and costs associated with CAR-T for cancer treatment and ongoing launch of lena PrEP- a preventative HIV drug